Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Vaccines

  Free Subscription


10.10.2022

1 Ann Intern Med
2 BMJ
3 Clin Infect Dis
1 J Immunol
9 J Infect Dis
2 J Pediatr
2 J Virol
1 JAMA
4 MMWR Morb Mortal Wkly Rep
2 Nat Med
1 Pediatr Infect Dis J
3 Pediatrics
1 PLoS Comput Biol
4 PLoS One
1 Science
22 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Intern Med

  1. GODDARD K, Hanson KE, Lewis N, Weintraub E, et al
    Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States.
    Ann Intern Med. 2022 Oct 4. doi: 10.7326/M22-2274.
    PubMed        


    BMJ

  2. SCHWALBE N, Varma JK
    The US needs to prepare to introduce the novel oral polio vaccine.
    BMJ. 2022;379:o2388.
    PubMed        

  3. FERDINANDS JM, Rao S, Dixon BE, Mitchell PK, et al
    Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study.
    BMJ. 2022;379:e072141.
    PubMed         Abstract available


    Clin Infect Dis

  4. BISWAL S, Patel SS, Rauscher M
    Safety of Dengue Vaccine?
    Clin Infect Dis. 2022 Oct 5. pii: 6748245. doi: 10.1093.
    PubMed        

  5. FIDLER S, Fox J, Tipoe T, Longet S, et al
    Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV.
    Clin Infect Dis. 2022 Oct 5. pii: 6748267. doi: 10.1093.
    PubMed         Abstract available

  6. PERNICIARO S, van der Linden M, Weinberger DM
    Re-emergence of Invasive Pneumococcal Disease in Germany during the Spring and Summer of 2021.
    Clin Infect Dis. 2022 Feb 7. pii: 6523816. doi: 10.1093.
    PubMed         Abstract available


    J Immunol

  7. ZHENG MZM, Fritzlar S, Wang Z, Tan TK, et al
    Cutting Edge: High-Dose Live Attenuated Influenza Vaccines Elicit Pulmonary Tissue-Resident Memory CD8(+) T Cells in the Face of Pre-Existing Humoral Immunity.
    J Immunol. 2022 Oct 5. pii: jimmunol.2200577. doi: 10.4049/jimmunol.2200577.
    PubMed         Abstract available


    J Infect Dis

  8. DE PIJPER CA, Langedijk AC, Terryn S, Van Gucht S, et al
    Long-term memory response after a single intramuscular rabies booster vaccination, 10-24 years after primary immunization.
    J Infect Dis. 2021 Jan 27. pii: 6121364. doi: 10.1093.
    PubMed         Abstract available

  9. EL SAHLY HM, Atmar RL, Sendra E, Wegel A, et al
    Topical Imiquimod Does not Provide an Adjuvant Effect when Administered with Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults.
    J Infect Dis. 2021 Apr 14. pii: 6225864. doi: 10.1093.
    PubMed         Abstract available

  10. RICHMOND PC, Hatchuel L, Pacciarini F, Hu B, et al
    Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine.
    J Infect Dis. 2021 Sep 4. pii: 6364149. doi: 10.1093.
    PubMed         Abstract available

  11. KIM SS, Chung JR, Belongia EA, McLean HQ, et al
    mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged >/=16 Years in the United States, February - May 2021.
    J Infect Dis. 2021 Sep 8. pii: 6366365. doi: 10.1093.
    PubMed         Abstract available

  12. VAN PRAET JT, Vandecasteele S, De Roo A, Vynck M, et al
    Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents.
    J Infect Dis. 2021 Sep 13. pii: 6369254. doi: 10.1093.
    PubMed         Abstract available

  13. KARBIENER M, Farcet MR, Schwaiger J, Powers N, et al
    Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins.
    J Infect Dis. 2021 Sep 20. pii: 6372887. doi: 10.1093.
    PubMed         Abstract available

  14. ASAMOAH-BOAHENG M, Goldfarb DM, Karim ME, O'Brien SF, et al
    The relationship between anti-spike SARS-CoV-2 antibody levels and risk of breakthrough COVID-19 among fully vaccinated adults.
    J Infect Dis. 2022 Oct 5. pii: 6748952. doi: 10.1093.
    PubMed         Abstract available

  15. CHAN CEZ, Wong SKK, Yazid NBM, Ng OT, et al
    Residual humoral immunity sustained over decades in a cohort of vaccinia-vaccinated individuals.
    J Infect Dis. 2022 Oct 6. pii: 6749013. doi: 10.1093.
    PubMed         Abstract available

  16. BENET S, Blanch-Lombarte O, Ainsua-Enrich E, Pedreno-Lopez N, et al
    Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PLWH with poor immune reconstitution.
    J Infect Dis. 2022 Oct 6. pii: 6749018. doi: 10.1093.
    PubMed         Abstract available


    J Pediatr

  17. BURKHARDT MC, Berset AE, Xu Y, Mescher A, et al
    Effect of Outreach Messages on Adolescent Well Child Visits and COVID-19 Vaccine Rates: An RCT.
    J Pediatr. 2022 Oct 3. pii: S0022-3476(22)00857.
    PubMed         Abstract available

  18. OLIVEIRA EA, Oliveira MCL, Colosimo EA, Simoes E Silva AC, et al
    Vaccine effectiveness against SARS-CoV-2 variants in adolescents from 15 to 90 days after second dose: a population-based test-negative case-control study.
    J Pediatr. 2022 Sep 28. pii: S0022-3476(22)00861.
    PubMed         Abstract available


    J Virol

  19. ELLIS-CONNELL AL, Balgeman AJ, Harwood OE, Moriarty RV, et al
    Control of Simian Immunodeficiency Virus Infection in Prophylactically Vaccinated, Antiretroviral Treatment-Naive Macaques Is Required for the Most Efficacious CD8 T Cell Response during Treatment with the Interleukin-15 Superagonist N-803.
    J Virol. 2022 Oct 3:e0118522. doi: 10.1128/jvi.01185.
    PubMed         Abstract available

  20. BONIFACIO JPPL, Williams N, Garnier L, Hugues S, et al
    Optimizing the Live Attenuated Influenza A Vaccine Backbone for High-Risk Patient Groups.
    J Virol. 2022 Oct 3:e0087122. doi: 10.1128/jvi.00871.
    PubMed         Abstract available


    JAMA

  21. ABBASI J
    White House Advisor Nahid Bhadelia, MD, MALD, on COVID-19 in Resource-Limited Nations-Undercounted Deaths, Vaccine Inequity, and More.
    JAMA. 2022 Oct 5. pii: 2797281. doi: 10.1001/jama.2022.13663.
    PubMed        


    MMWR Morb Mortal Wkly Rep

  22. PAYNE AB, Ray LC, Kugeler KJ, Fothergill A, et al
    Incidence of Monkeypox Among Unvaccinated Persons Compared with Persons Receiving >/=1 JYNNEOS Vaccine Dose - 32 U.S. Jurisdictions, July 31-September 3, 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:1278-1282.
    PubMed         Abstract available


  23. QuickStats: Percentage* of Residential Care Communities(dagger) that Offer Annual Influenza Vaccination to Residents and to Employees and Contract Staff Members, by Community Bed Size - United States, 2020.
    MMWR Morb Mortal Wkly Rep. 2022;71:1291.
    PubMed        

  24. PEREZ A, Lively JY, Curns A, Weinberg GA, et al
    Respiratory Virus Surveillance Among Children with Acute Respiratory Illnesses - New Vaccine Surveillance Network, United States, 2016-2021.
    MMWR Morb Mortal Wkly Rep. 2022;71:1253-1259.
    PubMed         Abstract available

  25. FOSTER MA, Hofmeister MG, Yin S, Montgomery MP, et al
    Widespread Hepatitis A Outbreaks Associated with Person-to-Person Transmission - United States, 2016-2020.
    MMWR Morb Mortal Wkly Rep. 2022;71:1229-1234.
    PubMed         Abstract available


    Nat Med

  26. BHATTACHARYA D, Victora GD
    Boosting with updated COVID-19 mRNA vaccines.
    Nat Med. 2022 Oct 6. pii: 10.1038/s41591-022-02048.
    PubMed        

  27. CHALKIAS S, Eder F, Essink B, Khetan S, et al
    Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
    Nat Med. 2022 Oct 6. pii: 10.1038/s41591-022-02031.
    PubMed         Abstract available


    Pediatr Infect Dis J

  28. KOIDE T, Nishigaki T
    A Case of Herpes Zoster Due to Varicella-Zoster Virus Vaccines in a 14-Month-old Girl.
    Pediatr Infect Dis J. 2022;41:860-861.
    PubMed         Abstract available


    Pediatrics


  29. Recommendations for Prevention and Control of Influenza in Children, 2022-2023.
    Pediatrics. 2022 Sep 6. pii: 189385. doi: 10.1542/peds.2022-059274.
    PubMed         Abstract available


  30. Recommendations for Prevention and Control of Influenza in Children, 2022-2023.
    Pediatrics. 2022 Sep 6. pii: 189387. doi: 10.1542/peds.2022-059275.
    PubMed         Abstract available

  31. FIKS AG, Hannan C, Localio R, Kelly MK, et al
    HPV Vaccinations at Acute Visits and Subsequent Adolescent Preventive Visits.
    Pediatrics. 2022 Oct 7. pii: 189684. doi: 10.1542/peds.2022-058188.
    PubMed        


    PLoS Comput Biol

  32. MATSUYAMA R, Yamamoto T, Hayama Y, Omori R, et al
    Measuring impact of vaccination among wildlife: The case of bait vaccine campaigns for classical swine fever epidemic among wild boar in Japan.
    PLoS Comput Biol. 2022;18:e1010510.
    PubMed         Abstract available


    PLoS One

  33. NIEMINEN H, Hakulinen T, Puumalainen T, Siren P, et al
    Time and labour costs of preventive health care, including vaccinations, in Finnish child health clinics.
    PLoS One. 2022;17:e0270835.
    PubMed         Abstract available

  34. LUN P, Gao J, Tang B, Yu CC, et al
    A social ecological approach to identify the barriers and facilitators to COVID-19 vaccination acceptance: A scoping review.
    PLoS One. 2022;17:e0272642.
    PubMed         Abstract available

  35. BOCKSTAL V, Shukarev G, McLean C, Goldstein N, et al
    First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
    PLoS One. 2022;17:e0274906.
    PubMed         Abstract available

  36. OKRUSZEK L, Piejka A, Banasik-Jemielniak N, Jemielniak D, et al
    Climate change, vaccines, GMO: The N400 effect as a marker of attitudes toward scientific issues.
    PLoS One. 2022;17:e0273346.
    PubMed         Abstract available


    Science

  37. COHEN J
    Uganda's Ebola outbreak will put novel vaccines to the test.
    Science. 2022;378:14-15.
    PubMed         Abstract available


    Vaccine

  38. SILVA-VALENCIA J, Soto-Becerra P, Escobar-Agreda S, Fernandez-Navarro M, et al
    Relative vaccine effectiveness of the booster dose of COVID-19 vaccine for preventing death in individuals with a primary regimen based on the BBIBP-CorV, ChAdOx1-S, or BNT162b2 vaccines during the Omicron wave in Peru: A nested case-control study usi
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01189.
    PubMed         Abstract available

  39. TEPEROWSKI MONRAD J, Quaade S, Powell-Jackson T
    Supply, then demand? Health expenditure, political leanings, cost obstacles to care, and vaccine hesitancy predict state-level COVID-19 vaccination rates.
    Vaccine. 2022 Sep 8. pii: S0264-410X(22)01041.
    PubMed         Abstract available

  40. TRAKARNVANICH T, Ngamvichchukorn T, Phumisantiphong U, Pholtawornkulchai K, et al
    Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01187.
    PubMed         Abstract available

  41. CERVANTES-TORRES J, Rosales-Mendoza S, Cabello C, Montero L, et al
    Towards the development of an epitope-focused vaccine for SARS-CoV-2.
    Vaccine. 2022 Sep 27. pii: S0264-410X(22)01168.
    PubMed         Abstract available

  42. LI L, Hessell AJ, Kong XP, Haigwood NL, et al
    A large repertoire of B cell lineages targeting one cluster of epitopes in a vaccinated rhesus macaque.
    Vaccine. 2021;39:5607-5614.
    PubMed         Abstract available

  43. PRESTON KB, Wong TAS, To A, Tashiro TE, et al
    Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvant.
    Vaccine. 2021;39:5650-5657.
    PubMed         Abstract available

  44. NOWAK SA, Gidengil CA, Parker AM, Matthews LJ, et al
    Association among trust in health care providers, friends, and family, and vaccine hesitancy.
    Vaccine. 2021;39:5737-5740.
    PubMed         Abstract available

  45. FOWLER A, Sampson M, Remaley AT, Chackerian B, et al
    A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice.
    Vaccine. 2021;39:5780-5786.
    PubMed         Abstract available

  46. KATZ S, Townsend-Payne K, Louth J, Lee-Jones L, et al
    Validation and use of a serum bactericidal antibody assay for Neisseria meningitidis serogroup X in a seroprevalence study in Niger, West Africa.
    Vaccine. 2022;40:6042-6047.
    PubMed         Abstract available

  47. RUSTANDI RR, Hamm M, Onimus M, Yuan Y, et al
    Monitoring bromide loss in bromoacetyl-derivatized polyribosylribitol polysaccharide in Haemophilus influenzae type b for PedvaxHIB(R) by capillary electrophoresis and NMR spectroscopy.
    Vaccine. 2022;40:6012-6016.
    PubMed         Abstract available

  48. LI L, Li Y, Bai Y, Li G, et al
    Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: A phase b randomized, double-blind, parallel-controlled study.
    Vaccine. 2022 Sep 16. pii: S0264-410X(22)01114.
    PubMed         Abstract available

  49. OSEI I, Sarwar G, Hossain I, Sonko K, et al
    Attendance and vaccination at immunization clinics in rural Gambia before and during the COVID-19 pandemic.
    Vaccine. 2022 Sep 13. pii: S0264-410X(22)01125.
    PubMed         Abstract available

  50. LIU B, Gidding H, Stepien S, Cretikos M, et al
    Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection.
    Vaccine. 2022 Sep 21. pii: S0264-410X(22)01126.
    PubMed         Abstract available

  51. DAY ME, Klein M, Sucharew H, Carol Burkhardt M, et al
    Declining influenza vaccination rates in an underserved pediatric primary care center during the COVID-19 pandemic.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01121.
    PubMed         Abstract available

  52. MERDRIGNAC L, Acosta L, Habington A, Garcia Cenoz M, et al
    Effectiveness of pertussis vaccination in pregnancy to prevent hospitalisation in infants aged <2 months and effectiveness of both primary vaccination and mother's vaccination in pregnancy in infants aged 2-11 months.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01160.
    PubMed         Abstract available

  53. TOLSTRUP WESTER C, Lybecker Scheel-Hincke L, Bovil T, Andersen-Ranberg K, et al
    Prayer frequency and COVID-19 vaccine hesitancy among older adults in Europe.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01153.
    PubMed         Abstract available

  54. PERRIER Q, Lupo J, Gerster T, Augier C, et al
    SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01064.
    PubMed         Abstract available

  55. NAKASHIMA K, Suzuki K, Aoshima M, Murabata M, et al
    Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study
    Vaccine. 2022 Sep 29. pii: S0264-410X(22)01163.
    PubMed         Abstract available

  56. MANJATE F, Quinto L, Chirinda P, Acacio S, et al
    Impact of rotavirus vaccination on diarrheal hospitalizations in children younger than 5 years of age in a rural southern Mozambique.
    Vaccine. 2022 Sep 30. pii: S0264-410X(22)01158.
    PubMed         Abstract available

  57. ROMER D, Winneg KM, Jamieson PE, Brensinger C, et al
    Misinformation about vaccine safety and uptake of COVID-19 vaccines among adults and 5-11-year-olds in the United States.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01154.
    PubMed         Abstract available

  58. LLOYD PC, Hu M, Wong HL, Shoaibi A, et al
    Near real-time surveillance of safety outcomes in US COVID-19 vaccine recipients aged 12 to 64 years.
    Vaccine. 2022 Sep 27. pii: S0264-410X(22)01167.
    PubMed         Abstract available

  59. ODIO CD, Katzelnick LC
    'Mix and Match' vaccination: Is dengue next?
    Vaccine. 2022 Oct 1. pii: S0264-410X(22)01101.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: